Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4
Endocrinology · 06.06.2023 · 164 (7)
DOI: 10.1210/endocr/bqad083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, online erschienen am 24.05.2023. Verfasst von Amy R Dwyer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA. Hauptthemen laut MEDLINE: Receptors, Glucocorticoid, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Corticosteroids act on the glucocorticoid receptor (GR; NR3C1) to resolve inflammation and are routinely prescribed to breast cancer patients undergoing chemotherapy treatment to alleviate side effects. Triple-negative breast cancers (TNBCs) account for 15% to 20% of diagnoses and lack expression of estrogen and progesterone receptors as well as amplified HER2, but they often express high GR levels. GR is a mediator of TNBC progression to advanced metastatic disease; however, the mechanisms underpinning this transition to more aggressive behavior remain elusive. We previously showed that tissue/cellular stress (hypoxia, chemotherapies) as well as factors in the tumor microenvironment (transforming growth factor β [TGF-β], hepatocyte growth factor [HGF]) activate p38 mitogen-activated protein kinase (MAPK), which phosphorylates GR on Ser134. In the absence of ligand, pSer134-GR further upregulates genes important for responses to cellular stress, including key components of the p38 MAPK pathway. Herein, we show that pSer134-GR is required for TNBC metastatic colonization to the lungs of female mice. To understand the mechanisms of pSer134-GR action in the presence of GR agonists, we examined glucocorticoid-driven transcriptomes in CRISPR knock-in models of TNBC cells expressing wild-type or phospho-mutant (S134A) GR. We identified dexamethasone- and pSer134-GR-dependent regulation of specific gene sets controlling TNBC migration (NEDD9, CSF1, RUNX3) and metabolic adaptation (PDK4, PGK1, PFKFB4). TNBC cells harboring S134A-GR displayed metabolic reprogramming that was phenocopied by pyruvate dehydrogenase kinase 4 (PDK4) knockdown. PDK4 knockdown or chemical inhibition also blocked cancer cell migration. Our results reveal a convergence of GR agonists (ie, host stress) with cellular stress signaling whereby pSer134-GR critically regulates TNBC metabolism, an exploitable target for the treatment of this deadly disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA.
- Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide, Adelaide, SA 5005, Australia.
- Department of Pathology and Laboratory Medicine and Center for Cancer Research, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.
- Signal Transduction Laboratory, Department of Health and Human Services, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, 27709, USA.
- Storr Liver Centre, The Westmead Institute for Medical Research and University of Sydney School of Medicine, Darlington, NSW, 2006, Australia.
- Departments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota, Minneapolis, MN, 55455, USA.
ORCID-Profile: Amy R Dwyer, Carol A Lange
Förderung
- Intramural NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- NIEHS NIH HHS
- National Institutes of Health's
- National Center for Advancing Translational Sciences
- Intramural Research Program
- NIEHS
Zitieren
APA
Dwyer, A. R., Perez Kerkvliet, C., Truong, T. H., Hagen, K. M., Krutilina, R. I., Parke, D. N., Oakley, R. H., Liddle, C., Cidlowski, J. A., Seagroves, T. N., & Lange, C. A. (2023). Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4. Endocrinology, 164(7). https://doi.org/10.1210/endocr/bqad083
Vancouver
Dwyer AR, Perez Kerkvliet C, Truong TH, Hagen KM, Krutilina RI, Parke DN, et al. Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4. Endocrinology. 2023;164(7). doi:10.1210/endocr/bqad083
BibTeX
@article{Dwyer2023,
author = {Dwyer, Amy R and Perez Kerkvliet, Carlos and Truong, Thu H and Hagen, Kyla M and Krutilina, Raisa I and Parke, Deanna N and Oakley, Robert H and Liddle, Christopher and Cidlowski, John A and Seagroves, Tiffany N and Lange, Carol A},
title = {Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4},
journal = {Endocrinology},
year = {2023},
volume = {164},
number = {7},
doi = {10.1210/endocr/bqad083}
}
EUVIMED